Which regimen is appropriate for cryptococcal pneumonia in an immunocompetent patient?

Which regimen is appropriate for cryptococcal pneumonia in an immunocompetent patient?

• A. Amphotericin B for 2 weeks
• B. Micafungin for 4 weeks
• C. Fluconazole or Itraconazole for 3-6 months
• D. Ketoconazole for 8 weeks

Answer: (C)

Treating pulmonary cryptococcosis in a person with a normal immune system relies on a prolonged course of an oral azole antifungal. Fluconazole or itraconazole are preferred because they effectively clear pulmonary infection, are well tolerated, and avoid the toxicity and IV administration required for amphotericin B. The typical regimen is a multi-month course, often 3–6 months, which allows the infection to resolve without the need for aggressive therapy. Why the other options aren’t ideal here: using amphotericin B, even for a couple of weeks, is more appropriate for severe disease or central nervous system involvement due to its toxicity profile; it isn’t needed for mild pulmonary disease in immunocompetent patients. Echinocandins like micafungin have little activity against Cryptococcus, so they aren’t effective. Ketoconazole is older, carries significant hepatotoxic risk and drug interactions, and a short 8-week course is less favorable than the longer azole therapy with fluconazole or itraconazole.

Treating pulmonary cryptococcosis in a person with a normal immune system relies on a prolonged course of an oral azole antifungal. Fluconazole or itraconazole are preferred because they effectively clear pulmonary infection, are well tolerated, and avoid the toxicity and IV administration required for amphotericin B. The typical regimen is a multi-month course, often 3–6 months, which allows the infection to resolve without the need for aggressive therapy.

Why the other options aren’t ideal here: using amphotericin B, even for a couple of weeks, is more appropriate for severe disease or central nervous system involvement due to its toxicity profile; it isn’t needed for mild pulmonary disease in immunocompetent patients. Echinocandins like micafungin have little activity against Cryptococcus, so they aren’t effective. Ketoconazole is older, carries significant hepatotoxic risk and drug interactions, and a short 8-week course is less favorable than the longer azole therapy with fluconazole or itraconazole.